84487-04-7

Basic information

• Product Name: CHEMPACIFIC 38154
• Synonyms: CHEMPACIFIC 38154;6-BROMO-3-NITRO-PYRIDIN-2-YLAMINE;2-Amino-6-bromo-3-nitropyridine;6-BROMO-3-NITROPYRIDIN-2-AMINE;6-Bromo-3-nitro-2-pyridinamine;2-AMino-6-broMo-3-nitropy...;6-Bromo-2-nitro-pyridin-3-ylamine
• CAS NO: 84487-04-7
• Molecular Formula: C₅H₄BrN₃O₂
• Molecular Weight: 218.01
• Mol File: 84487-04-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 199-202°
• Boiling Point: 349.519 °C at 760 mmHg
• Flash Point: 165.183 °C
• Appearance: Yellow to green/Solid
• Density: 1.93 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.683
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -1.73±0.50(Predicted)
• CAS DataBase Reference: CHEMPACIFIC 38154(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMPACIFIC 38154(84487-04-7)
• EPA Substance Registry System: CHEMPACIFIC 38154(84487-04-7)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 84487-04-7(Hazardous Substances Data)

Usage

General Description

CHEMPACIFIC 38154 is a chemical compound used in various industrial applications. It is a proprietary mixture of ingredients designed to provide a range of functions, such as corrosion inhibition, scale inhibition, and pH control. This chemical has been formulated for use in water treatment systems, particularly in cooling towers and boiler systems. It is designed to effectively control the buildup of scale and corrosion, and to help maintain the proper pH levels within the system. CHEMPACIFIC 38154 is a versatile and effective solution for maintaining the efficiency and longevity of industrial water systems.

InChI:InChI=1/C5H4BrN3O2/c6-4-2-1-3(9(10)11)5(7)8-4/h1-2H,(H2,7,8)

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 55304-80-8 2,6-dibromo-3-nitropyridine 
• 1643-19-2 tetrabutylammomium bromide 
• 73896-36-3 6-methoxy-3-nitropyridin-2-amine 

Downstream Products

• 538372-32-6 6-amino-5-nitro-pyridine-2-carboxylic acid methyl ester 
• 538372-33-7 5,6-diamino-pyridine-2-carboxylic acid methyl ester 
• 538372-35-9 2-(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-yl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid methyl ester 
• 538372-36-0 2-(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-yl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid 
• 129012-04-0 2,3-Diamino-6-bromopyridine 
• 1221350-07-7 3-nitro-6-(2-trifluoromethyl-phenyl)-pyridin-2-ylamine 
• 1332876-06-8 2-(3-tert-butyl-isoxazol-5-yl)-5-(2-trifluoromethyl-phenyl)-1H-imidazo[4,5-b]pyridine 
• 1332876-08-0 3-tert-butyl-isoxazole-5-carboxylic acid [3-nitro-6-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-amide 
• 1332876-14-8 2-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-5-(2-trifluoromethyl-phenyl)-1H-imidazo[4,5-b]pyridine 
• 102266-15-9 2-amino-3-nitro-6-phenylpyridine 
• 1609389-81-2 C₃₀H₃₀N₆O₅ 
• 1616405-99-2 2-(2-amino-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-(2,4-dichlorophenyl)ethanol 
• 1616406-48-4 2-(2-amino-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-(2,4-dichlorophenyl)ethanone 

Relevant articles and documents

Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents

Whole-cell high-throughput screening of the AstraZeneca compound library against the asexual blood stage of Plasmodium falciparum (Pf) led to the identification of amino imidazoles, a robust starting point for initiating a hit-to-lead medicinal chemistry effort. Structure-activity relationship studies followed by pharmacokinetics optimization resulted in the identification of 23 as an attractive lead with good oral bioavailability. Compound 23 was found to be efficacious (ED90 of 28.6 mg·kg-1) in the humanized P. falciparum mouse model of malaria (Pf/SCID model). Representative compounds displayed a moderate to fast killing profile that is comparable to that of chloroquine. This series demonstrates no cross-resistance against a panel of Pf strains with mutations to known antimalarial drugs, thereby suggesting a novel mechanism of action for this chemical class.

NOVEL BENZIMIDAZOLE DERIVATIVES

A compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is -N(S02R4)-, - N (COR5) - or -CO-; Y is -C (R6) (R7)_,-0- or -N (R8)_, provided that the compound (I) when E is nitrogen, n is 0, X is -CO-, and Y is -0- is excluded) is useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome, hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation (Pickwickian syndrome), sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, and increased anesthetic risk.

Substituted benzimidazoles and imidazo-[4,5]-pyridines

2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.